An experimental test that detects
a specific protein in blood samples appears to be promising as
a screening test for breast cancer, the manufacturer, Matritech,
Inc. of Newton, Massachusetts announced on Thursday.The test
detects nuclear matrix protein (NMP), a protein that may be elevated
in the blood of people with cancer. The test is approved in the
US, Japan and Europe for bladder cancer screening, but not for
other purposes. In a new study, the test was used in 78 women
who had early or advanced breast cancer, a precancerous condition,
or no cancer at all. The test correctly identified all cancer
cases, and four out of five women with a precancerous condition
known as ductal carcinoma in situ. ``We detected every case of
cancer, and ruled out cancer for all normal samples,'' David
L. Corbet, president and COO of Matritech, said. ``Based on this...we
consider 'proof of concept' complete.''
However, due to the small number of specimens, which came from
patients that the company knew did or did not have cancer ahead
of time, Dr. Clifford Hudis, chief of breast cancer medicine
services at Memorial Sloan-Kettering Cancer Center, expressed
concerns that the test may not be accurate with larger patient
populations. ``If (the test) has even a low rate of false-positive
results...(and you test) a million people...then you have thousands,
literally, of positive results that don't indicate cancer,''
he said in an interview with Reuters Health. False-positive results
occur when a test signals the presence of a disease, but the
patient does not in fact have the disease.
Thanks to Reuters Health (and BreastcancerNetwork)
Federation of Euro Cancer Soc., 3/02
Oncotype DX (TM) Breast Cancer Assay
Hem/Onc News, posted here 4/07
3rd European Breast Cancer Conference,
Mayo Clinic, posted here 4/07
NASA press release,
J Nuclear Medicine, 4/02
New York Times, Editorial Page,
The Breast Journal, 7/03
Breast Ca Res & Treat, 3/04
A Novel Molecular-Targeted Prognostic Immunohistochemistry Test for the Risk Profiling of ER+ Breast Cancer Patients
LINK: "Mammostrat is a five-antibody prognostic test for estrogen receptor-expressing, hormone receptor-treated (tamoxifen) breast cancer patients with node-negative disease".
LINK: "Acute trauma to the breast occurs in seat belt injuries producing hematomas that may result in permanent scars. Chronic trauma in the form of environmental toxins may predispose to breast cancer".
"The combined use of breast sonograms with Doppler blood flow study will provide early detection of most highly malignant cancers resulting in life saving early diagnosis and sparing the patient radical surgery. This result requires special training by the physician & state of the art sonograms".
|Remember we are NOT Doctors and have NO medical training.|
This site is like an Encyclopedia - there are many pages, many links on many topics.
Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.